Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Apr;75(4):e13911.
doi: 10.1111/ijcp.13911. Epub 2020 Dec 14.

Bone morphogenetic protein-2 against iliac crest bone graft for the posterolateral fusion of the lumbar spine: A meta-analysis

Zhenyu Wu  1 , Bo Zhou  2 , Liang Chen  2 , Xiaofeng Wang  3 , Mohamed E A Abdelrahim  4 , Cheng Wei  5
Affiliations
Meta-Analysis

Bone morphogenetic protein-2 against iliac crest bone graft for the posterolateral fusion of the lumbar spine: A meta-analysis

Zhenyu Wu et al. Int J Clin Pract. 2021 Apr.

Abstract

Background: The impact of bone morphogenetic protein-2 compared to autologous iliac crest bone graft to improve fusion rates for the posterolateral fusion of the lumbar spine remains inconclusive. This meta-analysis was performed to evaluate this relationship.

Methods: A systematic literature search up to May 2020 was performed and 14 studies were detected with 1516 subjects with 789 of them were bone morphogenetic protein-2 and 727 of them were autologous iliac crest bone graft. They reported relationships between bone morphogenetic protein-2 and autologous iliac crest bone graft on fusion rates for the posterolateral fusion of the lumbar spine. Odds ratio (OR) with 95% confidence intervals (CIs) was calculated comparing the bone morphogenetic protein-2 or autologous iliac crest bone graft on the posterolateral fusion of the lumbar spine risks using the dichotomous and continuous method with a random- or fixed-effect model.

Results: Bone morphogenetic protein-2 had significantly higher fusion rates (OR, 4.19; 95% CI, 2.82-6.20, P < .001); lower surgery time (OR, -26.64; 95% CI, -38.71 to -14.57, P < .001); lower blood loss (OR, -92.84; 95% CI, -131.71 to -53.97, P < .001); lower additional surgical procedures (OR, 0.46; 95% CI, 0.31-0.69, P < .001) and higher Oswestry Disability Index (OR, 1.49; 95% CI, 0.02-2.97, P = .05) compared to autologous iliac crest bone graft. However, no significant difference was found between bone morphogenetic protein-2 and autologous iliac crest bone graft in non-union rates (OR, 0.34; 95% CI, 0.08-1.53, P < .001); hospitalisation days (OR, -0.21; 95% CI, -0.48 to 0.07, P = .14) and adverse events (OR, 0.78; 95% CI, 0.52-1.16, P = .22).

Conclusions: Bone morphogenetic protein-2 significantly had a higher fusion rate, lower surgery time, lower blood loss, lower additional surgical procedures and higher Oswestry Disability Index compared to autologous iliac crest bone graft. This relationship forces us to recommend bone morphogenetic protein-2 for the posterolateral fusion of the lumbar spine to avoid any possible negative postoperative results.

PubMed Disclaimer

References

REFERENCES

    1. Hurlbert RJ, Alexander D, Bailey S, et al. rhBMP-2 for posterolateral instrumented lumbar fusion: a multicenter prospective randomized controlled trial. Spine. 2013;38:2139-2148.
    1. Cho JH, Lee JH, Yeom JS, et al. Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial. Spine J. 2017;17:1866-1874.
    1. Hreha J, Krell ES, Bibbo C. Role of recombinant human bone morphogenetic protein-2 on hindfoot arthrodesis. Foot Ankle Clinics. 2016;21:793-802.
    1. Lykissas M, Gkiatas I. Use of recombinant human bone morphogenetic protein-2 in spine surgery. World J Orthopedics. 2017;8:531.
    1. Wozney JM. Overview of bone morphogenetic proteins. Spine. 2002;27:S2-S8.

Publication types

LinkOut - more resources